LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced that its lead compound, LB-100, is the world's first and only clinical-stage inhibitor of protein phosphatase 2A (PP2A). This positions the company uniquely in the oncology landscape, as LB-100 aims to improve cancer treatment outcomes by making cancer cells more sensitive to immunotherapy and chemotherapy while disrupting the cancer's internal repair system.
The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by over 25 published preclinical and translational studies. According to the company, LB-100 introduces a potential new treatment paradigm by targeting PP2A, a key enzyme involved in cell growth and survival pathways.
LIXTE's proprietary small-molecule PP2A inhibitor is designed to enhance the effectiveness of existing cancer therapies. The company's press release notes that LB-100 has shown promise in preclinical models, and the ongoing clinical development aims to confirm these benefits in patients.
For more information, please refer to the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
